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Epitopes in the Linker Subdomain Region
of Envoplakin Recognized by Autoantibodies
in Paraneoplastic Pemphigus Patients
Bingxin Zhang1, Rui Zheng1, Jing Wang1, Dingfang Bu1 and Xuejun Zhu1
Sera from paraneoplastic pemphigus (PNP) immunoprecipitate multiple antigens from human epidermal
protein extract. In this study, we further characterized the autoantibodies in 12 PNP sera. Immunoblotting using
recombinant linker subdomains of envoplakin, periplakin, desmoplakin, and bullous pemphigoid antigen I
found that 11 of the 12 sera recognized linker subdomains of envoplakin and periplakin. We then synthesized 12
peptides covering the linker subdomain of envoplakin for ELISA. One of the peptides, peptide no. 8, was
recognized by nine out of the 12 sera with a higher affinity. A method of ligand–receptor binding assay was
designed and performed using this peptide labeled with fluorescence as the ligand. Peptide no. 8 bound to
CD20þ cells in Castleman’s tumors from the patients whose sera were positive to this peptide by ELISA. Our
data suggest that the linker subdomain of plakin proteins may be one of the major areas recognized by PNP
autoantibodies, and epitopes in the linker subdomain of envoplakin recognized by PNP autoantibodies with
a high affinity are dispersed in several areas and are variable among PNP patients. We also demonstrate that
B-lymphocyte clones specifically reacting to epidermal proteins exist in Castleman’s tumors from PNP.
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INTRODUCTION
Paraneoplastic pemphigus (PNP) is an autoimmune blistering
skin disease, characterized by severe mucosal erosions and
various cutaneous lesions, associated with lymphoprolifera-
tive diseases, such as non-Hodgkin’s lymphoma, Castleman’s
tumor, thymoma, follicular dendritic cell sarcoma. and
chronic lymphocytic leukemia (Anhalt et al., 1990; Camisa
and Helm, 1993; Kaplan et al., 2004). In China, PNP is
frequently found in association with Castleman’s tumors
(Wang et al., 2004).
One of the characteristic features in PNP is the presence of
serum autoantibodies that recognize proteins in stratified
squamous epithelia as well as transitional columnar and
simple epithelia (Fullerton et al., 1992; Anhalt, 2004). PNP
sera immunoprecipitate multiple antigens migrating on
immunoblotting at 250, 230, 210, 190, and 170 kDa bands
from protein extract of cultured human keratinocytes (Camisa
et al., 1992; Oursler et al., 1992; Hashimoto et al., 1995).
The 250, 230, and 190 kDa antigens have been identified as
desmoplakin I, bullous pemphigoid antigen I (BPAG1), and
periplakin, respectively (Stanley, 1993; Kim et al., 1997;
Kiyokawa et al., 1998). The 210 kDa antigen is found to be a
doublet. The upper band is desmoplakin II and the lower
band is later identified as envoplakin (Oursler et al., 1992;
Ruhrberg et al., 1996; Kim et al., 1997). The 170 kDa antigen
is a transmembrane cell surface protein yet to be identified.
ELISA also shows that PNP sera react against desmoglein 3
and desmoglein 1, the autoantigens for pemphigus vulgaris
(PV) and pemphigus foliaceus (PF) (Amagai et al., 1998).
Consequently, serum autoantibodies are more complicated
in PNP than in PV, PF, and bullous pemphigoid (BP).
Envoplakin (the 210 kDa band) and periplakin (the 190 kDa
band) were always recognized by our PNP patients and the
previously reported series (Rybojad et al., 1993; Borradori
et al., 1998; Kiyokawa et al., 1998; Joly et al., 2000;
Mimouni et al., 2002; Nikolskaia et al., 2003). The plakin
protein family includes envoplakin, periplakin, desmoplakin,
BPAG1, and plectin, which connect cytoskeletal networks to
each other and to desmosomes or hemidesmosomes. In skin
biopsy of PNP, direct immunofluorescence shows IgG and
complement C3 deposit on keratinocyte cell surface
and epidermal basement membrane zone (Nikolskaia
et al., 2003). The characteristic skin changes are suprabasi-
lar acantholysis, intraepidermal cleavage, and keratinocyte
necrosis.
The epitopes recognized by PNP sera were located in
multiple segments of envoplakin and periplakin by immuno-
blotting using rcombinant truncated envoplakin and peripla-
kin as the antigens (Nagata et al., 2001). In a study defined to
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a limited area, the linker subdomains in the carboxyl-terminal
regions of the five plakin family members were used as the
antigens, and all PNP sera tested recognized the linker
subdomains of envoplakin and periplakin (Mahoney et al.,
1998). The linker subdomain is the region that links the C
repeat subdomain to the precede domain (Ruhrberg et al.,
1997; Leung et al., 2001). In the carboxyl-terminal regions of
plakin family members, the linker subdomains and the A, B,
and C repeats are highly homologous, but periplakin lacks
the A, B, and C repeat domains (Ruhrberg et al., 1997).
Therefore, the linker subdomains are ideal to search for
immunodominant sequences in the carboxyl-terminal region
of envoplakin and periplakin.
In this study, we first characterized the antigenicity of the
linker subdomains of envoplakin, periplakin, desmoplakin,
and BPAG1 to our 12 PNP sera. Eleven out of the 12 PNP sera
reacted against the linker subdomains of envoplakin and
periplakin. We then used 12 peptides covering the linker
subdomain of envoplakin as the antigens for ELISA to furhter
delineate the areas of major epitopes in this region. The
antigenicity of the 12 peptides to the 12 PNP sera varied and
one of the peptides was found to be recognized by nine out of
the 12 sera with a higher affinity. A method of ligand–receptor
binding assay was designed and performed using this peptide
labeled with fluorescence as the ligand to probe the specific
immunoglobulin receptors on B lymphocytes in tumors from
PNP patients. The characterization of PNP autoantibodies has
the implications for the further understanding of autoimmune
mechanism in this disease.
RESULTS
PNP sera immunoblotting to the recombinant linker sub-
domains of envoplakin, periplakin, desmoplakin, and BPAG1
Sequence alignment of the recombinant linker sub-domains of
envoplakin, periplakin, desmoplakin, and BPAG1 used as the
antigens for immunoblotting demonstrates that the four
recombinant proteins contain a highly homologous region
spanning about 99 amino-acid residues (Figure 1). In the 12
PNP sera, 11 sera (from cases 1–5 and 7–12) reacted to the
linker subdomain of envoplakin, 11 sera (from cases 1–11) to
that of periplakin, seven sera (from cases 1 and 6–11) reacted to
that of desmoplakin and nine sera (from cases 1–2, 4–6, and
9–12) to that of BPAG1 (Figure 2). Every serum bound to
at least two of the four recombinant proteins, and four PNP
sera (from cases 1, 9–11) bound to all of the four proteins.
None of the sera recognized glutathione-S-transferase protein.
Sera from PV, PF, BP, and normal individuals were negative
to any of the four recombinant proteins. Consequently,
linker subdomains of envoplakin, periplakin, desmoplakin, and
BPAG1 are important areas recognized by PNP autoantibodies.
PNP sera recognizing the peptides covering linker subdomain of
envoplakin
To further characterize the areas of major epitopes located in
the linker subdomain of envoplakin, ELISA was used for the
assay of PNP sera recognizing the overlapped 12 peptides
covering this region. As shown in Table 1, peptides no. 3, 4,
5, 6, and 8 were recognized by 9 or 10 sera, and peptides no.
9, 11, and 12 by only 1 or 2 sera. PNP sera exhibited various
profiles of specificity and affinity in reacting to the 12
peptides (Table 1). For example, serum from case 1
recognized 10 peptides, and sera from cases 7 and 11 only
recognized three out of the 12 peptides. Serum from case 6
was negative to all of the 12 peptides, comparable to its
negative result of immunoblotting to the linker subdomain of
envoplakin. The affinity of the PNP sera binding to the 12
peptides can be evaluated by the net OD490 readings from
ELISA (Figure 3, panel a). To most of the sera, peptide no. 8
showed the highest net OD490, and peptides no. 1, 4, 6, 9, 11,
and 12 presented normal or slightly higher net OD490. Sera
from other autoimmune blistering diseases against these
peptides were also tested as the controls. Most sera from PV,
PF, and BP were found to have negligible, if any, net OD490
to the 12 peptides when compared with that of the normal
controls, except that two BP samples showed higher net
OD490 to peptides no. 7 and 8. BP sera recognized synthetic
peptides representing sequences in the carboxyl domain
of BPAG1 (Rico et al., 1990). Probably, the positive ELISA of
our BP sera to peptides 7 and 8 resulted from the highly
homology in the linker regions between envoplakin and
BPAG1 (Figure 1).
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Figure 1. Sequence alignment of recombinant linker domains of envoplakin,
periplakin, desmoplakin, and BPAG1 we used as the antigens for ELISA.
Black shaded letters, identical amino acids; gray shaded and light gray shaded
letters, highly conservative and conservative amino-acid changes among the
four proteins. Underlined letters are sequence of peptide no. 8 used as the
probe to examine the specific antigen receptor on surface membrane of B
lymphocytes in tumor sections.
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Figure 2. Immunoblotting of PNP sera to the recombinant linker subdomains
of envoplakin, periplakin, desmoplakin, and BPAG1. 1–12: sera from PNP
cases 1–12; PV: serum from a PV patient; PF: serum from a PF patient;
BP: serum from a BP patient; N: serum from a normal individual.
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Table 1. PNP sera recognizing the peptides covering the linker subdomain of envoplakin by ELISA
PNP case
Peptide no. 1 2 3 4 5 6 7 8 9 10 11 12 Positive cases
1 + +  + +   +  +  + 7/12
2 + + + + +    + +   7/12
3 + + + + +   + + + + + 10/12
4 + + + + +   + + + + + 10/12
5 + + + + +  + + + +   9/12
6 + + + +   + + + + +  9/12
7  +  +    + +   + 5/12
8 + +  + +  + + + +  + 9/12
9 +            1/12
10 +   +    + + +  + 6/12
11 +        +    2/12
12   +       +   2/12
+, positive, defined as the net OD490 larger than 2 net OD490 of upper 95% confidence interval from normal controls.
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Figure 3. Affinity of PNP sera binding to the 12 peptides covering the linker subdomain of envoplakin by ELISA. The affinity of serum binding to the 12
peptides is presented as net OD490. The short and horizontal line in each column marks the 2 net OD490 of upper 95% confidence interval from normal
controls. The upper figure of panel a shows the results of the 12 PNP sera. Numbers above the lines denote the case numbers of PNP, and sera with net OD490
below the upper limit are only indicated as circles in columns. The lower figure of panel a is the results of the controls. Squares, rhombuses, and triangles
represent sera from PV, PF, and BP, respectively. Panel b is the results of competitive ELISA. The upper figure of panel b used PNP sera pre-incubated with the
peptides same as those coated on the wells. The lower figure used the PNP sera pre-incubated with peptides PERI-L, DESM-L, or BPAG1-L to react with peptide
no. 8 on the wells. Serum of case 1 was not available any more in this test.
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When the tested PNP sera were pre-incubated with the
peptides same as those coated on the wells, almost all of the
positive OD490 readings were inhibited (Figure 3, panel b),
indicating that the positive OD490 readings are peptide
specific. Competitive ELISA using PNP sera pre-incubated
with the peptides corresponding to peptide no. 8 in
periplakin, Desmoplakin, and BPAG1 to recognize peptide
no. 8 on the wells showed that the OD490 readings decreased
only partially (Figure 3, panel b). Subsequently, a few parts of
the epitopes in peptide no. 8 are shared among the plakin
antigens.
Because that most OD490 readings of the positive results
were relatively low, not larger than OD490 0.2 above the
normal upper limit (Figure 3, panel a), and that the binding
capacity of small peptides on wells may be different, we also
performed dot blot to evaluate the significance of the ELISA
results. When the dot blot results (Figure 4) were compared
with those of ELISA in panel a of Figure 3, we can see that
most of the positive dot blot were in PNP sera having positive
ELISA to the same peptides only with higher OD490 readings.
For PNP sera to peptide no. 8, the two methods were
comparable. However, for peptide no. 11, dot blot seemed
more sensitive than ELISA, but for peptide no. 5 dot blot did
not detect the sera from cases 9 and 10 with higher ELISA
OD490 readings. Therefore, our ELISA using small peptides as
the antigens is essentially more sensitive than dot blot, but
some deviations between the two methods exist possibly
arising from variable binding ability of small peptides on
different substrate.
B-lymphocytes in Castleman’s tumors recognizing the peptide
in the linker subdomain of envoplakin
Peptide no. 8, which was recognized with a higher affinity by
nine out of the 12 PNP sera, was used as the ligand to test the
specific antigen receptors on surface membrane of B cells in
tumor slides. We performed the ligand–receptor binding test
for 10 tumors (tumor of case 1 was unavailable and tumor
sample of case 2 was in the necrosis area). Peptide no. 8
conjugated with green fluorescence was found on the surface
of tumors cells from cases 4, 5, 7, 8, 9, and 12, of which
ELISA results to peptide no. 8 were also positive. In the
tumors stained with green, the green (peptide no. 8) and red
(CD20) staining was predominantly seen in lymphoid
follicles. In most sites, the green staining overlapped the red
staining, indicating that peptide no. 8 mainly bound to the
surface of CD20þ B lymphocytes. Because of the uneven
distribution of green staining in tumors, we could not
estimate the intensity of the green staining in these tumor
slides. Negative staining of peptide no. 8 and positive staining
of anti-CD20 antibody were found in tumors from cases 3, 6,
and 11. In cases 3, 6, and 11, their sera were also negative to
this peptide by ELISA. However, the green and red staining
was not seen in tumor slides from case 10 (thymoma), despite
her serum was positive to this peptide by ELISA. In tonsil
sections, most CD20þ cells were in lymphoid follicles, but
no peptide no. 8 staining was seen. The control peptide was
negative to the tumors and the tonsil sections (Figure 5).
When the peptide no. 8 ligand was pre-absorbed by the
protein A beads coupling with antibodies from PNP sera of
cases 4, 5, 7, 8, and 9 the green staining turned to be very
weak in their respective tumor sections (Figure 5), but the
green staining remained using tumor section of case 8 and the
peptide no. 8 ligand pre-absorbed by the beads treated with
normal control serum.
DISCUSSION
The presence of autoantibodies reacting against desmoplakin,
envoplakin, periplakin, and BPAG1 in the epidermis is one of
the characteristics of PNP. These autoantigens belong to the
plakin family, a family of large modular proteins link keratin
intermediate filaments and desmosomes/hemidesmosomes
to maintain cell integrity and cell junction. The pathological
skin changes are acantholysis, vacuolar interface changes,
keratinocyte necrosis, and IgG deposition on epithelial
surface. These findings establish that PNP is essentially an
antibody-mediated autoimmune lesion of epithelial adhe-
sion. However, T lymphocytes must play an essential role in
PNP, and several evidences of cellular autoimmunity in PNP
have been described (Nguyen et al., 2001). Unlike PF, PV,
and BP in which desmoglein 1, desmoglein 3, or bullous
pemphigoid antigen 2 are primarily involved, PNP serum
reacts against multiple epidermal proteins. Plakins are
intracellular proteins, what factor(s) trigger the autoimmune
processes and how they become autoantigens are totally
unknown. In this study, we used synthetic peptides to
characterize the areas of major epitopes in the linker
subdomain of envoplakin, because envoplakin is always
recognized by PNP sera and its linker subdomain is highly
homologous to that of other plakin members (Figure 1).
Three characteristic features of the autoimmunity in PNP
patients were observed from this study. First, the linker
subdomain may be one of the major areas recognized by PNP
autoantibodies. In the 12 PNP sera, 10 sera reacted to three or
four of the four linker subdomains. The linker subdomains of
envoplakin and periplakin were recognized by 11 of the 12
sera. The alignment of the four linker subdomains we used
shows that they are highly homologous (Figure 1), especially
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Figure 4. Dot blot of PNP sera to the peptide no. 1–12. Sera of cases 1 and 3
were not available any more for this test. N: serum from a normal individual.
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in those of envoplakin and periplakin. Therefore, there may
be common epitopes recognized by PNP autoantibodies in
the four linker subdomains.
Second, in the linker subdomain of envoplakin, epitopes
recognized by PNP autoantibodies with a high affinity are
dispersed in several areas and are variable among PNP
patients. For example, sera from cases 2, 7, 8, and 12 mainly
reacted to peptides no. 8 with a high affinity, but sera from
cases 3, 5, and 11 only reacted to several peptides with a very
low affinity (Figure 3). Serum from case 6 was negative to the
12 peptides by ELISA and the recombinant linker subdomain
of envoplakin by immunoblotting.
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Figure 5. Cells in tumor sections stained by peptide no. 8 and anti-CD20 antibody. Double staining of tumor cells by peptide no. 8 or the control peptide
(green) and anti-human CD20 antibody (red) was observed by confocal laser scanning microscope. (a–c) A tumor section from case 8 was immunostained by
peptide no. 8 and anti-human CD20 antibody, showing the (a) green staining, (b) red staining, and (c) combination of the two images. Mixed green and red
staining appears orange in the merged figure. Peptide no. 8 staining locates on the surface of tumor cells and fits well with the CD20 staining, suggesting that the
specific membrane immunoglobulin receptors locate predominately on CD20þ cells. (d–f) A lymphoid follicle structure from case 12 was shown, it was double
stained by peptide no. 8 and anti-human CD20 antibody. (g–i) The tonsil section was immunostained by peptide no. 8 and anti-human CD20 antibody. (j–l) The
section was immunostained by the control peptide and anti-human CD20 antibody. No green staining beyond background was detected in (g) and (j), suggesting
that the binding of peptide no. 8 to the surface of CD20þ cells is specific. (m–o) Peptide no. 8 was pre-absorbed by a serum from PNP case 8 and then
immunostained the tumor section from the same PNP case. The green staining became very weak.
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Third, B-lymphocyte clones specifically reacting to epi-
dermal proteins exist in Castleman’s tumors associated with
PNP. We previously reported that autoantibodies could be
detected in cultured medium of Castleman’s tumor cells. To
further prove this observation, we designed a method of
antigen binding to membrane immunoglobulin receptors
on B cells in tumor sections. Appropriate negative controls
were always included in this assay. Positive results were only
seen in Castleman’s tumors from the patients whose sera
were positive to this peptide in ELISA. Lymphoid follicle
structures, in which CD20þ B-lymphocytes cluster, showed
the strongest staining by the peptide probe. Moreover, amino-
acid sequence of peptide no. 8 has no similarity to that of any
proteins in the protein database other than plakins (http://
www.ncbi.nlm.nih.gov). These results confirm our previous
proposal that secreted autoantibody from Castleman’s tumor
can be an essential factor in the pathogenesis of PNP
(Wang et al., 2004). In patients with thymoma and follicular
dendritic cell sarcoma, however, binding of peptide no. 8 to
tumor B cells was negative but ELISA using this peptide as
the antigen was positive in case 10 (thymoma), suggesting
that they may be different from PNP with Castleman’s tumor
in autoantibody production. Lymphocytes in thymus and
dendrite cells act on many important immunological
processes. Accordingly, PNP associated with these tumors
may have different autoimmune mechanisms.
One explanation to the wide distribution of epitopes in
plakin family proteins is the phenomenon of epitope
spreading in which autoimmune reactions initially against
one autoantigen injure the dermoepidermal junction, result-
ing in the exposure of self-antigens and activation of lym-
phocytes specific to these antigens (Bowen et al., 2000; Chan,
2000). Our observation does not support this hypothesis.
If epitope spreading happened in PNP, autoantibodies to
plakin proteins would be produced in immunological system
rather than in Castleman’s tumors.
MATERIALS AND METHODS
Sera from PNP patients
Sera were obtained from 12 PNP patients admitted to the
Department of Dermatology, Peking University First Hospital
during 1998 to 2004 (Table 2). These patients showed typical
clinical and histopathological features associated with Castleman’s
tumor, thymoma, or follicular dendritic cell sarcoma (Nguyen et al.,
2001). By using immunofluorescence, sera from these patients
reacted to transitional epithelia on mouse urinary bladder with
the titers of 1:40 to 1:1,280. On immunoblotting using protein
extract from culture human keratinocytes as the antigens, all the sera
recognized the proteins of 250, 210, and 190 kDa. We also used sera
from 12 cases of PV, 12 cases of PF, 12 cases of BP, and 24 normal
individuals as the controls. The study was conducted according to
the Declaration of Helsinki Principles and approved by the Medical
Ethical Committee of the Peking University First Hospital. All
patients gave informed consent.
Immunoblotting of PNP sera using recombinant linker
subdomains of envoplakin, periplakin, desmoplakin, and BPAG1
as the antigens
The linker subdomains of envoplakin, periplakin desmoplakin, and
BPAG1 were cloned by reverse transcription PCR. Total RNA
extracted from human keratinocytes was reversely transcribed into
first strand cDNA. Four pairs of PCR primers were designed to
amplify the cDNA fragments encompassing the nucleotides coding
amino acids 1,678–1,812 of envoplakin (NP_001979, forward
primer: 50-ATGCGGATCCGAGAGACCAACCTTTCCACCAA, re-
verse primer: 50-ACGTGAATTCAGAAGAAACTGGTGCTCTGGG),
Table 2. Clinical manifestations and associated tumors of the 12 PNP patients
Mucosal lesions Skin lesions Tumor
Case
no.1 Sex
Age
(year) Oral Ocular Anal-genital
Erythema
multiforme-like
Lichen
planus-like Pemphigus-like
Palmoplantar
keratosis Type Location
1 M 39 + + + + + + Ct Ret
2 M 17 + + + + + Ct Ret
3 M 30 + + + Ct Ret
4 F 25 + Ct Med
5 F 17 + + + Ct Med
6 M 29 + + + + + + Ct Ret
7 F 22 + + + + + + Ct Ret
8 F 48 + + + + + Ct Ret
9 F 41 + + + + + Ct Ret
10 F 57 + + + + Thymoma Med
11 F 26 + + + + + FDCS Ret
12 M 36 + + + + + + + Ct Ret
1The clinical characteristics of cases no. 1–7 and no. 10–11 have been published in our previous reports (Wang et al., 2004, 2005).
Ct: Castleman’s tumor; FDCS: follicular dendritic cell sarcoma; Med: mediastinum; Ret: retroperitoneum.
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amino acids 1,615–1,755 of periplakin (NP_002696, forward primer:
50-ATGCGGATCCTGGAGAGGGAACTGGATGAC, reverse primer:
50-ACGTGAATTCATCTGCCCAGATACCAAGACC), amino acids
2,461–2,601 of desmoplakin (NP_004406, forward primer: 50-ATG
CGGATCCTCCTCAGGAAGCGTAGAGTGG, reverse primer: 50-AC
GTGAATTCAATTCCTGACGCTGGATATGG), and amino acids
2,316–2,445 of BPAG1 (NP_001714, forward primer: 50-ATGCGGA
TCCAGTCCCAATGCTTTCTGTTTCC, reverse primer: 50-ACGTGAA
TTCATGCAAATCTTTCTTGGGGAC). PCR products were digested
with BamHI and EcoRI, ligated in frame into plasmid pGEX-3X
(Pharmacia, Piscataway, NJ), sequenced to confirm the reading frame
and the sequences, and expressed in E. coli DH5a. The fusion protein
was purified in a glutathione Sepharose 4B column, separated by
SDS-PAGE and transferred onto a nitrocellulose membrane. Purified
glutathione-S-transferase protein was used as the negative control.
The membranes were blotted by the patients’ sera.
Preparation of peptides covering the linker subdomain of
envoplakin
Our immunoblotting results demonstrated that 11 of the 12 PNP sera
recognized the linker subdomains of envoplakin and periplakin, and we
then tried to further determine the areas of major epitopes in the linker
subdomain of envoplakin specific to the PNP sera. Twelve peptides, of
which each contains 20 amino-acid residues, were synthesized. The
alignment of the 12 peptides and their correspondent positions in the
linker subdomain are shown in Figure 6. Eleven of them are overlapped
each other covering a large part of the linker subdomain. Each of the 11
overlapped peptides differs from its neighbor peptide in only seven
amino acids so that all epitopes in this region can be detected. These
peptides were used as the antigens for ELISA.
ELISA of PNP sera using the peptides as the antigens
ELISA plate was coated with the peptides at the concentration of
100mg/ml in 0.1 M sodium carbonate buffer (pH 9.6) at 41C
overnight. After washing with phosphate-buffered saline (PBS)/
0.05% Tween-20 and blocking with 3% BSA in PBS/0.05%
Tween-20, 50 ml of PNP serum or control serum diluted to 1:500
in PBS/0.05% Tween-20 were added to a well and the plate was
incubated at 371C for 2 hours. After extensive washing with PBS/
0.05% Tween-20 for 3 times, 50 ml alkaline phosphatase conjugated
goat anti-human IgG antibody diluted to 1:1,000 were added to each
well and the plate was incubated for 2 hours at 371C. After washing
with PBS/0.05% Tween-20, the bound secondary antibody was
developed with phosphatase substrate for 20 minutes and measured
at OD490 by using an ELISA plate reader. The test was duplicated in
two independent assays for each sample. The net OD490 of a serum
sample was determined by subtracting the average OD490 of blanks
from OD490 of the sample. The upper OD490 value of 95%
confidence interval for normal population was determined by the
parametric methods. A PNP serum was considered to be positive
when its net OD490 exceeded the upper OD490 value of 95%
confidence interval for normal population by two folds.
To verify the specificity of the ELISA results, 10ml of PNP serum or
control serum was pre-incubated with one of the 12 peptides, each
containing 500 ng, at 41C overnight. The serum was then diluted to
1:500, added to the well coated with the peptide same as that pre-
incubated with the serum and subjected to competitive ELISA as
described above. Competitive ELISA was also performed to clarify
whether the epitopes in peptide no. 8 are shared among the plakin
antigens. Three peptides corresponding to the place of peptide no. 8
in periplain, desmoplakin, and BPAG1 were prepared (Figure 1):
PERI-L: IHDRKSGKKFSIEEALQSGR; DESM-L: LVDRKTGSQYDIQ-
DAIDKGL; and BPAG1-L: LTDTKTGLHFNINEAIEQGT. Positive sera
to peptide no. 8 from cases 2, 4, 5, 7, 8, 9, 10, and 12 were tested
for the competitive ELISA. Ten microliters of PNP serum were pre-
incubated with 1,000 ng of peptide PERI-L, DESM-L, or BPAG1-L at
41C overnight. The serum was then diluted to 1:500, added to the
wells coated with peptide no. 8 to conduct the competitive ELISA.
Dot blot of PNP sera using the peptides as the antigens
To further confirm the ELISA results, 5 mg of the peptide were dotted
on a nitrocellulose membrane. After incubation in blocking solution
at room temperature for 1 hour, the membrane was blotted with
1:500 PNP or control sera. Blotted antibody was visualized by
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Figure 6. Peptide sequence for the localization of areas of major epitopes to PNP autoantibodies. Domain structure of envoplakin is shown at the upper line.
N, amino-terminal globular domain; R, central coiled-coil rod domain; C, C-subdomain; L, linker subdomain (Ruhrberg et al., 1996). Peptides are aligned to
show their correspondent positions in the linker subdomain of envoplakin.
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horseradish peroxidase-conjugated goat anti-human IgG antibody
and diaminobenzidine staining.
Ligand–receptor binding assay to identify specific immuno-
globulin receptors on B-lymphocytes in tumors
The ELISA results demonstrated that peptide no.8 was bound by nine
of the 12 PNP sera with a higher affinity. The peptide no. 8 was then
used as a ligand to probe the specific antigen receptors on B
lymphocytes in tumors. An unrelated peptide was used as a negative
control. The sequence of the control peptide is IRRSILPYGDSM-
DRIEKD, which locates in the NC16a domain of 180 kDa bullous
pemphigoid antigen 2 recognized by BP patients (Matsumura et al.,
1996). The two peptides were conjugated with FITC and used as the
probes in this assay.
Surgical specimens of tumors from 10 PNP patients stored at
801C and a normal tonsil from a tonsillectomy operation were
embedded in OCT medium (Sakura Fine Technica, Tokyo, Japan).
Cryostat sections in 6 mm thickness were mounted on slides and
stored at 801C until use. After washing with PBS for 3 minutes and
3 times, sections were blocked with 3% BSA/0.1% Tween-20/PBS at
room temperature for 30 minutes. Sections were rinsed with PBS and
covered with 1:200 mouse anti-human CD20 monoclonal antibody
(Zymed, San Francisco, CA) in 3% BSA/0.1% Tween-20/PBS at room
temperature for 1 hour. After washing with 0.1% Tween-20/PBS for
3 minutes and 3 times, a mixture containing 5mg/ml peptide no. 8 or
the control peptide conjugated with FITC and 1:200 goat anti-mouse
IgG antibody conjugated with tetramethylrhodamine isothiocyanate
(TRITC) (Jackson, West Grove, PA) in 3% BSA/0.1% Tween-20/PBS
was applied on sections and the slides were incubated at 41C
overnight. After washing with PBS/0.1% Tween-20 for 10 minutes and
3 times, the slides were mounted with 90% glycerol and examined
by using a confocal laser scanning microscope (Leica TCS SP2,
Germany) equipped with an argon-ion laser (excitation light 488 nm
for FITC) and a helium neon green laser (excitation light 543 nm for
TRITC) and mounted on a Dmire2 microscope (Leica, Germany).
Pre-absorption of the peptide no. 8 ligand by PNP sera was used
to test the specificity of the assay. Fifty microliters of sera from cases
4, 5, 7, 8, and 9 and a normal control serum were incubated
with 50 ml protein A Sepharose (Amersham Biosciences, Sweden)
for 3 hours. After washing with PBS/0.1% Tween-20 for 3 times, the
protein A Sepharose beads were added to the FITC-conjugated
probes and incubated at 41C overnight. The supernatants were used
for the ligand–receptor binding assay on tumor sections from cases 4,
5, 7, 8, 9, and 8, respectively.
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